Qlaris Bio appoints Robert Warner to board of directors

pharmafile | February 16, 2026 | Appointment | |  Qlaris Bio 

Qlaris Bio has appointed Robert Warner to its board of directors.

Warner brings significant experience in life sciences leadership to his new role. Prior to a sabbatical, he spent more than 13 years at Alcon, where he held roles including President US and Canada and President and General Manager Alcon Vision Care Franchise. During his time at Alcon, Warner built his expertise in a variety of areas, including corporate strategy, financing and company building.

Warner also serves on the boards of various organisations in the biotechnology and medical device sectors.

Advertisement

The appointment of Warner to Qlaris’ board of directors will help to drive the company’s growth as it advances its lead development programme through late-stage clinical trials. The programme, QLS-111, is a treatment for glaucoma. It has shown promise in phase 2 clinical trials to date, with indications in open angle glaucoma and ocular hypertension.

Thurein Htoo, CEO of Qlaris, said: “Robert’s experience as a global commercial leader in ophthalmology will be an important asset as Qlaris continues to advance QLS‑111 through our next phase of clinical development.”

Warner added: “The team has made impressive progress advancing a truly differentiated approach to glaucoma treatment.”

Qlaris is a clinical-stage biotechnology company specialising in the development of treatments for glaucoma.

Related Content

No items found
The Gateway to Local Adoption Series

Latest content